Cargando…
Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID-19
INTRODUCTION: Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD), lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in pat...
Autores principales: | Steffens, Younès, Le Bon, Serge-Daniel, Lechien, Jerome, Prunier, Léa, Rodriguez, Alexandra, Saussez, Sven, Horoi, Mihaela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336533/ https://www.ncbi.nlm.nih.gov/pubmed/35904632 http://dx.doi.org/10.1007/s00405-022-07560-y |
Ejemplares similares
-
Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell
por: Le Bon, Serge-Daniel, et al.
Publicado: (2021) -
Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report
por: Lechien, Jerome R., et al.
Publicado: (2023) -
Platelet-rich plasma injection in the olfactory clefts of COVID-19 patients with long-term olfactory dysfunction
por: Lechien, Jerome R., et al.
Publicado: (2022) -
Injection of Platelet Rich Plasma in the Olfactory Cleft for COVID-19 Patients With Persistent Olfactory Dysfunction: Description of the Technique
por: Lechien, Jerome R., et al.
Publicado: (2022) -
Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study
por: Saussez, Sven, et al.
Publicado: (2021)